Champions Oncology, Inc. splits its revenue into 3 lines in its filings. The largest line in Q1 of fiscal 2027, the quarter ended Jul 31, 2026 was Pharmacology Services at $14.2 million, 93% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jul 31, 2026
|
Q1 FY2027
Jul 31, 2026
|
Q4 FY2026
Apr 30, 2026
|
Q3 FY2026
Jan 31, 2026
|
Q2 FY2026
Oct 31, 2025
|
Q1 FY2026
Jul 31, 2025
|
Q4 FY2025
Apr 30, 2025
|
Q3 FY2025
Jan 31, 2025
|
Q2 FY2025
Oct 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
61
|
15
|
14
|
17
|
15
|
14
|
12
|
17
|
13
|
| Pharmacology Services |
58
+19.1%
share 95.7%
|
14
+7.0%
share 92.9%
|
13
+16.4%
share 95.4%
|
16
+38.7%
share 97.7%
|
15
+16.1%
share 96.5%
|
13
share 94.5%
|
11
share 91.8%
|
12
share 68.5%
|
12
share 92.7%
|
| Translational Oncology Solutions TOS License Revenue |
1
share 2.2%
|
1
+187.1%
share 5.9%
|
0
+68.2%
share 2.1%
|
—
|
0
share 1.0%
|
0
share 2.2%
|
0
share 1.4%
|
4
share 26.4%
|
—
|
| Product And Service Other |
1
-60.0%
share 2.1%
|
0
-59.7%
share 1.2%
|
0
-59.7%
share 2.4%
|
0
-56.8%
share 2.3%
|
0
-63.4%
share 2.4%
|
0
share 3.2%
|
1
share 6.7%
|
1
share 5.1%
|
1
share 7.3%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CSBR (Nasdaq)
- Fiscal year ends
- April 30
- Incorporated in
- DE
- Headquarters
- Baltimore, MD
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 771856
- Former names
- CHAMPIONS BIOTECHNOLOGY, INC. (until Mar 30, 2011); CHAMPIONS SPORTS INC (until Feb 16, 2007)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.